Diacerein Cream for Adults With Plaque Psoriasis
Tests diacerein cream against placebo cream in adults with psoriasis vulgaris.
Key facts
- Who runs it
- Alaa Ashraf Muhammad Helal
- Where
- Cairo, EgyptSee the site
- Trial code
- Registry title
- Topical Diacerein in Psoriasis Vulgaris
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 60 people, planned
- Started
- 11 Apr 2026
- Expected to end
- 1 May 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Diacerein
- Placebo
- Record updated
- 22 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with mild long-lasting plaque psoriasis. It tests a cream with diacerein 1% against a placebo cream.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Mild chronic plaque psoriasis: body surface area (BSA) under 10%, PASI score under 10 and/or DLQI score under 10
- Earlier treatment
- No psoriasis treatment by mouth or injection (systemic) in the last 3 months, and no skin creams or other topical treatment in the last 2 weeks
Main reasons for not taking part
- Allergy to the trial product or anything in the cream
- Pustular psoriasis
- Psoriatic arthritis
- Pregnant or breast-feeding
- Systemic psoriasis treatment in the last 3 months or topical treatment in the last 2 weeks
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Age ≥18 years old of both genders
- Patients with mild chronic plaque psoriasis body surface area (BSA < 10%) along with Psoriasis Area and Severity Index (PASI) score of < 10, and/or Dermatology Life Quality Index (DLQI) score of <10
Who cannot take part
- Documented hypersensitivity or idiosyncratic reaction to the investigational product or any excipients contained within the cream formulation
- Intake of anti-psoriatic systemic therapy within the last 3 months, or topical treatments within the last 2 weeks
- Patients with pustular psoriasis
- Pregnant and breast-feeding individuals
- Patients with psoriatic arthritis
Where in Egypt
- Kasr Al-Ainy Psoriasis UnitCairo, EgyptContact: Yousra A Azzazi, PhD, Faculty of MedicineTaking people
About the trial
What the trial wants to find out
The goal of this clinical trial is to evaluate the safety and effectiveness of topical diacerein in adults with psoriasis vulgaris. The primary objective of the study is to compare the proportion of participants who achieve a clinically meaningful improvement in disease severity between the topical diacerein group and the placebo group.
Read full original descriptionShow less
Participants will:
Be assigned to receive topical diacerein 1% or placebo twice daily for a treatment period of 2 months.
Attend follow-up visits at Weeks 2, 4, 6, and 8. Undergo an additional evaluation one month after treatment cessation.
The 2 groups in the trial
- Topical DiacereinTreatment being tested
Participants assigned to this arm will receive topical diacerein cream 1% applied twice daily for a treatment period of two months.
Treatment: Diacerein
- PlaceboPlacebo, for comparison
Participants assigned to this arm will receive a matching placebo topical cream applied twice daily for a treatment period of two months.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The Efficacy of Topical Diacerein Cream in Patients With Psoriasis Vulgaris
- Plain-language title
- Diacerein Cream for Adults With Plaque PsoriasisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 22 October 2026